This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Natali, P. G. Articles by Ferrone, S. Search for Related Content PubMed PubMed Citation Articles by Natali, P. G. Articles by Ferrone, S.

Heterogeneity in the Expression of HLA and Tumor-associated Antigens by Surgically Removed and Cultured Breast Carcinoma Cells¹

Regina Elena Cancer Institute, Rome, Italy [P. G. N., P. G., A. B., M. R. N.], and Departments of Pathology, and Surgery, College of Physicians and Surgeons, Columbia University, New York, New York 10032 [K. I., A, K. N., S. F.]

Surgically removed normal and malignant mammary tissues and human breast carcinoma cell lines were tested in binding assays with monoclonal antibodies to HLA-A,B,C antigens, β²-microglobulin, HLA-DR antigens, and tumor-associated antigens; the latter included a M_r 280,000, a M_r 94,000, and a M_r 85,000 membrane-bound glycoprotein and a cytoplasmic antigen. HLA-A,B antigens, β₂-microglobulin, HLA-DR antigens, and the cytoplasmic antigen are expressed by normal mammary cells. Their malignant transformation may be associated with quantitative changes in the expression of these antigens and with the appearance of M_r 94,000 and Mr 85,000 glycoproteins. The M_r 280,000 glycoprotein was detected on only one of the breast carcinoma cell lines tested. Analysis of primary tumors and autologous axillary lymph node metastasis from 13 patients has shown differences in the expression of all the antigens tested between primary and metastatic lesions.

¹ This work was supported by NIH Grants AI 19189, CA 32609, CA 32619, CA 32634, and CA 32635, and CNR Grant "Controllo Crescita Neoplastica" 810132696.

² Recipient of a fellowship in Cancer Immunology of the Cancer Institute of New York.

Received 2/ 8/82. Accepted 10/28/82.

This article has been cited by other articles:

				Y. Miura, C. J. Thoburn, E. C. Bright, W. Chen, S. Nakao, and A. D. Hess Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD Blood, September 18, 2002; 100(7): 2650 - 2658. [Abstract] [Full Text] [PDF]

				M. Feinmesser, A. Sulkes, S. Morgenstern, J. Sulkes, S. Stern, and E. Okon HLA-DR and {beta}2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities J. Clin. Pathol., April 1, 2000; 53(4): 286 - 291. [Abstract] [Full Text] [PDF]

				A. D. Hess, E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, and M. J. Kennedy Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide Blood, March 15, 1997; 89(6): 2203 - 2209. [Abstract] [Full Text] [PDF]

				J. R. Houck, F. M. Sexton, and G. Zajdel HLA Class I and Class II Antigen Expression on Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, October 1, 1990; 116(10): 1181 - 1185. [Abstract] [PDF]